Clinical Trial Update: Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase Ib/II study evaluating LY2780301 in combination with weekly paclitaxel for HER2-positive metastatic br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• LY2780301 (LY2780301)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED